ConductScience.org, home

Paper36949121

Cancer cells remodel nuclear actin filaments to resist chemotherapy.

Panier S. Nature, 2023. Cited by 2 papers, by iCite.

Cite this record

ConductScience Library. Cancer cells remodel nuclear actin filaments to resist chemotherapy. Papers, record 36949121. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36949121

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Cancer cells remodel nuclear actin filaments to resist chemotherapy.
PubMed
Journal
Nature
PubMed
Year
2023
PubMed
Publication types
News, Comment
PubMed
Citations, by iCite
2
iCite
Relative citation ratio, by iCite
0.15
iCite
Revised in PubMed
2026-10-30
PubMed

Authors1

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Panier SStephaniehttps://orcid.org/0000-0002-7941-2846

Source PubMed

Download CSV of authors

Topics4

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Actin CytoskeletonMajor topic
NeoplasmsMajor topic
Cell Nucleus
Actins

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment on36949199RHOJ controls EMT-associated resistance to chemotherapy.https://conductscience.org/library/papers/36949199

Source PubMed

Download CSV of comments and corrections

References14

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
123706631DNA-damaging agents in cancer chemotherapy: serendipity and chemical biology.Chem Biol2013https://conductscience.org/library/papers/23706631PubMed
233257806Nuclear F-actin counteracts nuclear deformation and promotes fork repair during replication stress.Nat Cell Biol2020https://conductscience.org/library/papers/33257806PubMed
324434213Vascular RhoJ is an effective and selective target for tumor angiogenesis and vascular disruption.Cancer Cell2014https://conductscience.org/library/papers/24434213PubMed
434541899Rho GTPase signaling in cancer progression and dissemination.Physiol Rev2022https://conductscience.org/library/papers/34541899PubMed
528982779Initiation of DNA replication requires actin dynamics and formin activity.EMBO J2017https://conductscience.org/library/papers/28982779PubMed
627301673Regulating Rho GTPases and their regulators.Nat Rev Mol Cell Biol2016https://conductscience.org/library/papers/27301673PubMed
732309283Targeting Rho GTPase Signaling Networks in Cancer.Front Cell Dev Biol2020https://conductscience.org/library/papers/32309283PubMed
822971344RhoJ regulates melanoma chemoresistance by suppressing pathways that sense DNA damage.Cancer Res2012https://conductscience.org/library/papers/22971344PubMed
934003341Cancer drug resistance induced by EMT: novel therapeutic strategies.Arch Toxicol2021https://conductscience.org/library/papers/34003341PubMed
1032300252Guidelines and definitions for research on epithelial-mesenchymal transition.Nat Rev Mol Cell Biol2020https://conductscience.org/library/papers/32300252PubMed
1136949199RHOJ controls EMT-associated resistance to chemotherapy.Nature2023https://conductscience.org/library/papers/36949199PubMed
1228085222Epithelial-mesenchymal transition in tumor metastasis.Mol Oncol2017https://conductscience.org/library/papers/28085222PubMed
1334902824NCCN Guidelines® Insights: Squamous Cell Skin Cancer, Version 1.2022.J Natl Compr Canc Netw2021https://conductscience.org/library/papers/34902824PubMed
1431481797Nuclear actin filaments in DNA repair dynamics.Nat Cell Biol2019https://conductscience.org/library/papers/31481797PubMed

Download CSV of references

Cited by2

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.

PMIDTitleJournalYearIn PapersSource
41102728Tropomodulin 1 is essential for chemotherapy sensitivity and associated with better outcome in triple-negative breast cancer.BMC Cancer2025https://conductscience.org/library/papers/41102728PubMed
40883257Cell Viability, Drug Screening, and Mechanism Study Under Mild Phototherapy Integrated Chemotherapy (PIC).Adv Sci (Weinh)2025https://conductscience.org/library/papers/40883257PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36949121

GET https://conductscience.org/api/papers/v1/36949121/authors